|
Accueil > Actualité
Roche: new positive data for lung cancer drug
(CercleFinance.com) - Roche has announced updated data from its pivotal Phase III ALEX study showing an increased five-year survival rate with Alecensa (alectinib), compared to crizotinib, in patients with ALK-positive non-small cell lung cancer.
"These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials," Roche said, which is presenting the full findings today, 29 May, at the ASCO20 virtual scientific program. Copyright (c) 2020 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
